JK-1201I
Phase 3Small molecule
JK-1201I is one of 109 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
3
Indications
5
Total Trials
3
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
JK-1201I
JJenKem Technology Co., Ltd.
Phase 3
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Adenocard
AstellasPreclinical
Voltaren
NovartisPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Spravato
WWim Janssens
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
Malignant Solid Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JK-1201I. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJenKem Technology Co., Ltd.